Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Radzikowska, E. Wiatr, R. Langfort, I. Bestry, K. Roszkowski (Warsaw, Poland). Organising pneumonia -clarithromycin treatment. Eur Respir J 2008; 32: Suppl. 52, 3470

Member's Comments

No comment yet.

Related content which might interest you: Compared efficacies of lung delivery using two nebulizers in the prophylaxis against pneumocystis carinii pneumonia Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016 Nebulised colistin for ventilator-associated pneumonia prevention Source: Eur Respir J 2015; 46: 1732-1739 Year: 2015 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Cryptogenic organizing pneumonia – Results of treatment with clarithromycin versus corticosteroids Source: International Congress 2016 – Orphan diseases II Year: 2016 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis Source: Eur Respir J 2010; 35: 858-864 Year: 2010 Delirium induced by clarithromycin in a patient with community-acquired pneumonia Source: Eur Respir J 2006; 28: 671-672 Year: 2006 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Immunostimulating therapy in treatment of Community-acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Antipyretic effect of dexamethasone in community-acquired pneumonia Source: Eur Respir J 2015; 46: 570-573 Year: 2015 Cost of treatment failure in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 195s Year: 2007 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007